K2 VBI Equity Trust Acquires VBI Vaccines in CCAA Restructuring

Vireo Growth Inc to Acquire Certain Assets of The Cannabist Company Holdings Inc

July 20, 2026

Healthcare Services

Vireo Growth Inc, through its subsidiary Vireo Health of Arcadia, LLC, entered into a definitive purchase agreement to acquire certain cannabis cultivation, manufacturing, and retail operations from subsidiaries of The Cannabist Company Holdings Inc across Colorado, Illinois, Massachusetts, New Jersey, and West Virginia. The deal consideration is up to US$35 million (subject to regulatory approvals), with closing expected in stages through 2026 and 2027. Vireo expects the transaction to add up to 25 dispensaries and strengthen its vertically integrated presence in multiple limited-license cannabis markets.

Eli Lilly to Acquire Vaccine Company for Up to $1.55 Billion

May 27, 2026

Biotechnology

Vaccine Company, Inc. announced it has entered into a definitive agreement to be acquired by Eli Lilly and Company in a deal valued at up to $1.55 billion, including upfront and milestone-based payments. The acquisition is intended to accelerate development of Vaccine Company’s next-generation in vivo nanoparticle (IVN) vaccine platform, led by a Phase 1-ready Epstein-Barr virus (EBV) vaccine candidate targeting infectious mononucleosis and longer-term EBV-linked diseases.

Kyyba Inc. Acquires Viki Technologies

March 16, 2023

Healthcare Services

Kyyba Inc./Kyyba Tech has agreed to acquire Viki Technologies, a specialist healthcare technology provider based in Farmington Hills, Michigan, for an undisclosed amount. The acquisition expands Kyyba's healthcare capabilities and will integrate Viki's clinical decision support and data-driven tools into Kyyba's broader healthcare solutions platform.

KKR-backed Biosynth Carbosynth Acquires vivitide; Ampersand Rolls Over Stake

March 17, 2022

Biotechnology

KKR has invested in Biosynth Carbosynth through its Health Care Strategic Growth Fund II, and Biosynth Carbosynth has acquired vivitide, a global provider of custom peptides and antibody services. Existing owner Ampersand Capital Partners rolled over its entire stake and will be a substantial minority shareholder in the combined global life‑sciences reagents and custom synthesis platform to accelerate geographic expansion, broaden capabilities, and expand the product portfolio.

Venture Life Group plc Acquires BBI Healthcare (BBIH) from Exponent

June 7, 2021

Consumer Products

Venture Life Group plc has agreed to acquire BBI Healthcare (BBIH), the consumer self-care division of BBI Group, from private equity owner Exponent. BBIH — owner of brands including Balance Activ, GlucoGel and LIFT with broad UK retail distribution and a Swedish manufacturing facility — was transformed under Exponent, delivering strong EBITDA growth; its managing director will leave on completion while the chairman will remain with BBI Group.

Merck & Co., Inc. Acquires VelosBio Inc.

November 5, 2020

Biotechnology

Merck & Co., Inc. will acquire all outstanding shares of clinical-stage biopharmaceutical company VelosBio for $2.75 billion in cash. The acquisition adds VelosBio's lead investigational antibody-drug conjugate VLS-101 and ROR1-directed pipeline assets to Merck's oncology portfolio and is expected to close by the end of 2020, subject to customary conditions.